Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning
Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sana Usman
- Phone Number: +923007154668
- Email: sunusman0@gmail.com
Study Contact Backup
- Name: Arif Mahmood, FCPS
- Phone Number: +923008730810
- Email: dr_arif_mahmood@yahoo.com
Study Locations
-
-
Punjab Province
-
Multan, Punjab Province, Pakistan, 60000
- Recruiting
- Nishtar Hospital/Medical University
-
Contact:
- Sana Usman
- Phone Number: +923007154668
- Email: sunusman0@gmail.com
-
Contact:
- Arif Mahmood, FCPS
- Phone Number: +923008730810
- Email: dr_arif_mahmood@yahoo.com
-
Principal Investigator:
- Sana Usman
-
Principal Investigator:
- Arif Mahmood
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Both genders
- Adult patients aged between 18 and 50 years
- Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route
- Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study
Exclusion Criteria:
- Patients with known allergy to MgSO4
- Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg/dl)
- Patients with documented pre-existing cardiac impairments (e.g., heart block)
- Pregnant or lactating women
- Confirmed intake of any other drug or poison
- Patients who will be declared dead on arrival or those who expired within 2 hours of presentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Atropine plus pralidoxime with MgSO4-Group
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
|
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
Patients will be treated with standard atropine plus pralidoxime therapy alone.
|
|
Experimental: Atropine plus pralidoxime-Group
Patients will be treated with standard atropine plus pralidoxime therapy alone.
|
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: 15 days after hospital admission
|
Frequency of patients will be noted who will die within 15 days to clinical stabilization.
|
15 days after hospital admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intermediate Syndrome (IMS)
Time Frame: 7 days after poisoning
|
Frequency of patients will be noted who will develop Intermediate Syndrome (IMS) within seven days of poisoning.
|
7 days after poisoning
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sana Usman, Nishtar Hospital Multan, Pakistan
- Study Director: Arif Mahmood, FCPS, Nishtar Hospital Multan, Pakistan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Poisoning
- Organophosphate Poisoning
- Organic Chemicals
- Heterocyclic Compounds
- Alkaloids
- Aza Compounds
- Heterocyclic Compounds, Bridged-Ring
- Atropine Derivatives
- Tropanes
- Azabicyclo Compounds
- Belladonna Alkaloids
- Solanaceous Alkaloids
- Bridged Bicyclo Compounds, Heterocyclic
- Atropine
- pralidoxime
Other Study ID Numbers
Other Study ID Numbers
- Dr-Sana-Nishter
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.